Wegovy Long Term Side Effects UK - From £69.00

Clinically Proven UK Registered Pharmacy

Cheapest Wegovy Long Term Side Effects UK Price - £69.00

Get Wegovy at the cheapest UK price from £69.00 with £20 off first order using code Weightlossnew.

UK-registered clinical team
Confidential and secure
No GP visit needed
Next-day delivery included — no hidden costs or surprise charges
Start Your Free Consultation

Takes less than 2 minutes to complete 100% online

Weightlossnew £20 off for new customers

Treatment from £69.00

Genuine Products
UK-licensed only
Fast Delivery
Next-day available
Expert Advice
UK pharmacists
Woman using Cured Pharmacy online consultation for weight loss treatment

Check your BMI

Height 175 cm
Weight 82 kg

Your BMI

26.8
Start Free Consultation

Free · BMI thresholds shown are illustrative. Final eligibility is confirmed by a UK prescriber during your free consultation.

LIVE PRICING

Our Pricing

Pricing Disclaimer: Prices on some pages may not be up to date — the live pricing table below and pricing shown during consultation are official current prices and take precedence over any other figures on the site.

Mounjaro (Tirzepatide)
Weeks 1–4

2.5mg

1 pen • 4 Weeks

£145 £124.99

£31.25 / Per Week

Your starting dose – designed to help your body adjust gently to treatment

⭐ Future Orders at £145
Start Consultation
Mounjaro (Tirzepatide)
Weeks 5–8

5mg

1 pen • 4 Weeks

£179 £159.00

£39.75 / Per Week

First step up – builds on your progress as your body adapts to treatment

⭐ Future Orders at £179
Start Consultation
Mounjaro (Tirzepatide)
Weeks 9–12

7.5mg

1 pen • 4 Weeks

£220 £200.00

£50.00 / Per Week

Mid-range dose – for continued progression and enhanced results

⭐ Future Orders at £220
Start Consultation
Mounjaro (Tirzepatide)
Weeks 13–16

10mg

1 pen • 4 Weeks

£245 £225.00

£56.25 / Per Week

Higher strength dose – supports significant weight loss progress

⭐ Future Orders at £245
Start Consultation
Mounjaro (Tirzepatide)
Weeks 17–20

12.5mg

1 pen • 4 Weeks

£270 £250.00

£62.50 / Per Week

Advanced dose – for patients requiring stronger therapeutic effect

⭐ Future Orders at £270
Start Consultation
Mounjaro (Tirzepatide)
Weeks 21+

15mg

1 pen • 4 Weeks

£287 £267.00

£66.75 / Per Week

Maximum dose – the highest available strength for optimal results

⭐ Future Orders at £287
Start Consultation
Wegovy (Semaglutide)
Weeks 1–4

0.25mg

1 pen • 4 Weeks

£89 £69.00

£17.25 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £89
Start Consultation
Wegovy (Semaglutide)
Weeks 5–8

0.5mg

1 pen • 4 Weeks

£109 £89.00

£22.25 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £109
Start Consultation
Wegovy (Semaglutide)
Weeks 9–12

1mg

1 pen • 4 Weeks

£119 £99.00

£24.75 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £119
Start Consultation
Wegovy (Semaglutide)
Weeks 13–16

1.7mg

1 pen • 4 Weeks

£169 £149.00

£37.25 / Per Week

Higher strength – supports accelerated weight loss progress

⭐ Future Orders at £169
Start Consultation
Wegovy (Semaglutide)
Weeks 17+

2.4mg

1 pen • 4 Weeks

£199 £179.00

£44.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199
Start Consultation
Wegovy (Oral Pill)
Weeks 1–4

1.5mg

1 pen • 4 Weeks

£83.00 £63.00

£20.75 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £83.00
Start Consultation
Wegovy (Oral Pill)
Weeks 5–8

4mg

1 pen • 4 Weeks

£110.00 £90.00

£27.50 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £110.00
Start Consultation
Wegovy (Oral Pill)
Weeks 9–12

9mg

1 pen • 4 Weeks

£140.00 £120.00

£35.00 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £140.00
Start Consultation
Wegovy (Oral Pill)
Weeks 13+

25mg

1 pen • 4 Weeks

£199.00 £179.00

£49.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199.00
Start Consultation

Understanding Wegovy Long Term Side Effects: What UK Patients Need to Know

Wegovy long term side effects are a critical consideration for UK patients embarking on extended semaglutide treatment for weight management. While clinical trials demonstrate sustained efficacy over multi-year periods, understanding the chronic safety profile helps patients and prescribers make informed decisions. Our UK-registered clinical team, led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), has supported thousands of patients through long-term GLP-1 therapy, and this guide consolidates the latest evidence on what to expect beyond the initial treatment phase.

Wegovy Long Term Side Effects: Clinical Trial Evidence

The STEP programme trials, particularly STEP 1 and STEP 5, provide the most robust data on Wegovy long term side effects in patients treated for 68 weeks and beyond [1]. In the extended STEP 5 trial evaluating 104 weeks of continuous semaglutide 2.4mg treatment, gastrointestinal side effects remained the most common adverse events, though their frequency and severity typically decreased after the initial 20-week dose escalation period [2]. Approximately 74% of participants experienced at least one gastrointestinal event during the full study duration, but fewer than 5% discontinued treatment specifically due to these symptoms in the chronic maintenance phase.

Importantly, serious adverse events occurred at comparable rates between semaglutide and placebo groups when assessed over the full trial duration (9.8% vs 6.4%), with no unexpected safety signals emerging in the extended observation period [1]. The most clinically significant long-term concerns identified include gallbladder-related disorders, with cholelithiasis (gallstones) occurring in 2.6% of semaglutide patients versus 1.2% on placebo, and a small but measurable increase in heart rate averaging 1-4 beats per minute that persists throughout treatment [2].

Chronic Gastrointestinal Effects of Wegovy Long Term Use

While nausea, vomiting, and diarrhoea are well-documented during Wegovy initiation, understanding the trajectory of these Wegovy long term side effects is essential for patient counselling. Data from the STEP trials show that gastrointestinal adverse events peak during weeks 0-20 of dose escalation, then decline substantially in both frequency and intensity [1]. By week 68, fewer than 8% of patients reported active nausea, compared to over 40% during the initial months.

However, a subset of patients experience persistent gastrointestinal symptoms that require ongoing management strategies. These chronic effects may include intermittent constipation (affecting approximately 20% of long-term users), occasional reflux symptoms, and altered bowel habits [2]. Our clinical experience at Cured Pharmacy suggests that patients who maintain consistent meal timing, adequate hydration (2-2.5 litres daily), and moderate fibre intake (25-30g daily) report significantly better gastrointestinal tolerance during extended treatment. Importantly, severe complications such as gastroparesis remain rare, with no confirmed cases directly attributable to semaglutide in the STEP trials, though post-marketing surveillance continues to monitor this potential risk.

Managing Persistent Gastrointestinal Symptoms

For patients experiencing ongoing Wegovy long term side effects in the gastrointestinal system, evidence-based management includes dose optimisation (some patients maintain efficacy on lower maintenance doses), dietary modification emphasising smaller frequent meals, and judicious use of over-the-counter remedies such as loperamide for diarrhoea or macrogol for constipation. Always consult your prescriber before adjusting your Wegovy regimen, as abrupt dose changes can paradoxically worsen symptoms.

Wegovy Long Term Side Effects on Gallbladder and Pancreatic Health

One of the most clinically significant Wegovy long term side effects involves the hepatobiliary system. Meta-analyses of GLP-1 receptor agonist trials, including the STEP programme, demonstrate a consistent 20-30% increased relative risk of gallbladder disorders, including cholelithiasis and cholecystitis, compared to placebo [3]. This risk appears mechanistically linked to rapid weight loss rather than semaglutide itself, as similar rates occur with bariatric surgery and very low-calorie diets.

The absolute risk remains modest—approximately 2-3% of patients over 1-2 years of treatment—but warrants specific patient education [3]. Symptoms requiring urgent medical assessment include severe right upper quadrant abdominal pain, particularly after meals, fever with abdominal pain, or jaundice. Regarding pancreatitis, while early GLP-1 trials raised theoretical concerns, the STEP programme found acute pancreatitis rates of 0.2% with semaglutide versus 0.1% with placebo, a difference not reaching statistical significance [1]. Current MHRA guidance acknowledges pancreatitis as a potential rare adverse effect but does not contraindicate GLP-1 therapy in patients without active pancreatic disease.

Treatment Type Frequency Starting Price
Wegovy (Semaglutide) Injection GLP-1 agonist Weekly from £89.00
Wegovy Oral Tablets GLP-1 agonist Daily from £83.00
Mounjaro (Tirzepatide) GLP-1/GIP agonist Weekly from £145.00
Saxenda (Liraglutide) GLP-1 agonist Daily from £68.00
Orlistat Lipase inhibitor Three times daily from £32.00
Mysimba Naltrexone/Bupropion Twice daily from £125.95

Thyroid and Endocrine Considerations for Wegovy Long Term Side Effects

Thyroid safety represents a critical area of ongoing surveillance for Wegovy long term side effects, driven by preclinical rodent studies demonstrating thyroid C-cell tumours at high semaglutide exposures [4]. Importantly, no cases of medullary thyroid carcinoma (MTC) have been confirmed as causally related to semaglutide in human clinical trials or post-marketing surveillance to date, and the biological relevance of rodent C-cell findings to human thyroid physiology remains uncertain.

Wegovy remains contraindicated in patients with personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and prescribers should maintain vigilance for symptoms such as a neck mass, dysphagia, or persistent hoarseness [4]. Routine calcitonin monitoring is not recommended by MHRA or NICE guidelines for patients without specific risk factors. Beyond thyroid considerations, long-term semaglutide use may affect other endocrine parameters: small increases in heart rate (average 2-4 bpm) persist throughout treatment, though without increased cardiovascular events in the STEP trials, and minor reductions in bone mineral density (approximately 1-2% at the hip) have been observed, likely secondary to weight loss rather than direct drug effect [2].

Monitoring Recommendations for Long-Term Wegovy Use

UK prescribers typically recommend baseline and periodic monitoring including renal function (eGFR), lipid profile, HbA1c (in patients with diabetes or prediabetes), and clinical assessment for gallbladder symptoms. While routine thyroid imaging is not indicated, patients should be counselled to report any neck swelling or difficulty swallowing promptly. At Cured Pharmacy, our clinical team ensures all patients receive comprehensive safety counselling and access to ongoing prescriber review throughout their Wegovy treatment journey.

Psychological and Quality of Life Aspects of Wegovy Long Term Side Effects

Emerging data on Wegovy long term side effects increasingly recognises psychological and quality of life dimensions beyond physical adverse events. The STEP trials employed validated instruments (SF-36, IWQOL-Lite) demonstrating sustained improvements in health-related quality of life metrics over 68-104 weeks, with particular gains in physical functioning, social functioning, and body image domains [1]. However, a subset of patients report psychological challenges during extended treatment, including anxiety about weight regain if treatment is discontinued, altered relationship with food and eating, and in rare cases, mood disturbances.

Post-marketing surveillance and real-world cohort studies have identified uncommon reports of depression and suicidal ideation in patients taking GLP-1 receptor agonists, though causality remains unestablished and confounding by obesity-related depression is significant [5]. The European Medicines Agency reviewed this signal in 2023 and concluded current evidence does not support a causal link, but prescribers should remain alert to mood changes, particularly in patients with pre-existing mental health conditions. Our experience at Cured Pharmacy emphasises the importance of holistic support, combining pharmacotherapy with behavioural strategies and regular clinical review to optimise both physical and psychological outcomes during long-term Wegovy use.

Balancing Wegovy Long Term Side Effects Against Clinical Benefits

When evaluating Wegovy long term side effects, the critical clinical question is whether the safety profile remains acceptable relative to sustained therapeutic benefit. The STEP 5 trial provides compelling evidence: patients maintaining semaglutide 2.4mg for 104 weeks achieved mean weight loss of 15.2% from baseline, compared to 2.6% with placebo, with sustained improvements in cardiometabolic parameters including blood pressure, lipids, and glycaemic control [1]. Importantly, weight loss was maintained throughout the second year of treatment without plateau, and adverse event-related discontinuation rates did not increase in the extended observation period.

For UK patients, accessing Wegovy at Cured Pharmacy from £69.00 (with £20 off first order using code Weightlossnew) provides an evidence-based option for long-term weight management, subject to prescriber approval following comprehensive clinical assessment. Our UK-registered clinical team ensures each patient receives individualised risk-benefit evaluation, ongoing safety monitoring, and access to specialist advice should any Wegovy long term side effects emerge during treatment. All Wegovy prescriptions require completion of our online clinical assessment by a UK-registered prescriber, ensuring treatment is appropriate, safe, and supported by regular review throughout your weight management journey.

When to Seek Medical Review During Long-Term Wegovy Treatment

Patients should contact their prescriber promptly if experiencing severe or persistent abdominal pain (particularly right upper quadrant), symptoms of pancreatitis (severe epigastric pain radiating to the back), changes in vision, signs of thyroid enlargement, significant mood changes, or any adverse effect impacting quality of life. At Cured Pharmacy, our clinical team remains accessible for ongoing support, and we encourage proactive communication to optimise safety and efficacy throughout your treatment course.

Scientific References

  1. Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., ... & Wharton, S. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083-2091. [accessed 15 August 2026]
  2. Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
  3. He, L., Wang, J., Ping, F., Yang, N., Huang, J., Li, Y., ... & Li, W. (2022). Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: A systematic review and meta-analysis of randomized clinical trials. JAMA Internal Medicine, 182(5), 513-519. [accessed 15 August 2026]
  4. Medicines and Healthcare products Regulatory Agency. (2023). Semaglutide (Wegovy): reminder of risk of thyroid C-cell tumours and medullary thyroid carcinoma. Drug Safety Update, 16(8). [accessed 15 August 2026]
  5. European Medicines Agency. (2023). Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 6-9 November 2023: GLP-1 receptor agonists and suicidal and self-injurious thoughts. EMA/PRAC/711645/2023. [accessed 15 August 2026]
  6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
  7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
  8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.

Trusted by thousands

Real people, real results

Jane L.

"Brilliant. Lost 4 stone on mounjaro no side effects at all. Cured pharmacy are excellent. Always helpful pens sent out quickly always comes with needles and sterile wipes. If you want to go on GLP-1 go to cured pharmacy. So professional. Thank you cured pharmacy you changed my health and well being."

Ann-Marie

"I absolutely love this product, I have been using 2.5mg as maintenance dose and have managed to control my weight without any side effects and can still eat well balanced meals. The pharmacy is very efficient friendly and helpful I would not purchase from anywhere else."

Sacha W.

"So far I'm really impressed by my results it's crazy cause I'm not snacking like how I used to do and I see my face slimming down already and it's only been 2 and a half weeks. Can't wait to give my feedback in 5 months time thank you cured pharmacy."

Kimberly G.

"Mounjaro has corrected my hormonal weight gain during menopause. I am using it now to maintain that balance. The results for me have been exceptional!"

Jennifer

"Great really helps cure those nasty habits can't wait for my next mounjaro pen."

How it Works?

Select from our recommended UK-licensed medications.

1

Choose your treatment

Step 1: Choose your treatment from Cured Pharmacy

Select safe UK treatments. Quick answers.

2

Answer quick questions

Step 2: Answer quick consultation questions

We will deliver direct to you as quickly as tomorrow.

3

Get it delivered fast

Step 3: Fast discreet delivery to your door

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today

Once you complete a short online assessment you will be able to choose your preferred treatment from safe medically approved options tailored to you.

Start My Assessment

Returning Customer?

Log in to Your Account

Faq

What are the most common Wegovy long term side effects after one year of treatment?
After one year, the most common Wegovy long term side effects are mild gastrointestinal symptoms affecting fewer than 10% of patients, including intermittent constipation, occasional nausea, and altered bowel habits. Serious adverse events remain rare, with gallbladder disorders affecting approximately 2-3% of long-term users.
Does the risk of Wegovy long term side effects increase or decrease over time?
Clinical trial data shows that most Wegovy long term side effects, particularly gastrointestinal symptoms, decrease in frequency and severity after the initial 20-week dose escalation period. Adverse event-related discontinuation rates do not increase in the second year of treatment compared to the first year.
Are there any serious Wegovy long term side effects I should watch for?
Serious Wegovy long term side effects requiring medical attention include severe abdominal pain (potentially indicating gallbladder or pancreatic issues), neck swelling or difficulty swallowing (thyroid concerns), significant mood changes, or persistent gastrointestinal symptoms affecting nutrition. Contact your prescriber promptly if these occur.
How do Wegovy long term side effects compare to other weight loss medications?
Wegovy long term side effects are predominantly gastrointestinal, similar to other GLP-1 agonists like Saxenda and Mounjaro, but generally better tolerated than older agents. Orlistat causes different side effects (fatty stools, urgency), while Mysimba may affect mood and blood pressure differently than semaglutide.
Can Wegovy cause permanent long term side effects?
Current evidence from trials extending to 104 weeks shows that most Wegovy side effects resolve upon treatment discontinuation. Gallstones, if they develop, may require intervention, but there is no evidence of permanent organ damage in patients without pre-existing contraindications who are appropriately monitored.
Will I need regular blood tests to monitor for Wegovy long term side effects?
UK prescribers typically recommend periodic monitoring of renal function, lipids, and HbA1c (if relevant), but routine thyroid or pancreatic blood tests are not required for patients without specific risk factors. Your prescriber will determine an appropriate monitoring schedule based on your individual health profile.
Do Wegovy long term side effects affect bone health or muscle mass?
Studies show minor reductions (1-2%) in bone mineral density during long-term Wegovy use, likely related to weight loss rather than direct drug effect. Maintaining adequate protein intake, resistance exercise, and calcium/vitamin D supplementation can help preserve muscle mass and bone health during treatment.
How much does long-term Wegovy treatment cost at UK pharmacies?
At Cured Pharmacy, Wegovy is available from £69.00 per prescription, with £20 off your first order using code Weightlossnew. All prescriptions require clinical assessment by our UK-registered prescribers to ensure long-term treatment remains safe and appropriate for your individual circumstances.
Tarun Kumar, Prescribing Pharmacist

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Reviewed on: June 03, 2026

Last reviewed: 15 August 2026

Last updated on 15 August 2026.

Review History

Our experts continually monitor new findings in health and medicine, and we update our articles when new information becomes available.

Why this page was updated on 15 August 2026

Content checked and updated as part of our periodic review, to ensure accuracy and currentness.

Current version (15 August 2026)

Edited by: The Editorial Team

Medically reviewed by:

Tarun Kumar, GPhC No. 2233073, Prescribing Pharmacist


How we source info.

When we present you with stats, data, opinion or a consensus, we'll tell you where this came from.